Back to results
US 2010/0166804 A1Published application
Methods
OwnerDennis Penninventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerDennis Penninventor
Estimating the term…
The present invention relates to methods of prophylactically treating, reducing, delaying or controlling severe allergic reaction, e.g., to food and/or hymenoptera allergen, e.g. peanut allergen or bee venom allergen, in patients at risk of systemic anaphylaxis, e.g., patients receiving allergen desensitization therapy, through the use of a mast cell stabilizer, e.g., ketotifen and/or its metabolites or derivatives in free or pharmaceutically acceptable acid addition salts thereof. The invention further provides methods to desensitize a patient to one or more allergens comprising administering (i) one or more allergen to induce tolerance and (ii) one or more mast cell stabilizers in free or pharmaceutically acceptable salt thereof.
A method for prophylactically treating, controlling, delaying or reducing severe reaction to allergen or symptoms of mediator release during allergen desensitization in a patient at risk of systemic anaphylaxis if exposed to such allergen, comprising:
A method for desensitizing a patient to an allergen comprising:
A method of allergen desensitization comprising:
A method of allergen desensitization comprising administering to a patient in need thereof (i) increasing doses of allergen to induce tolerance and (ii) an amount of at least one antihistamine to inhibit symptoms of mediator release.
A method of allergen desensitization comprising administering to a patient in need thereof (i) increasing doses of allergen to induce tolerance and (ii) an amount of one or more mast cell stabilizer in free or pharmaceutically acceptable acid addition salt form effective to inhibit symptoms of mediator release.
A method of allergen desensitization comprising administering to a patient in need thereof (i) increasing doses of allergen to induce tolerance and (ii) an amount of a compound having dual antihistamine and mast cell stabilizing activities to inhibit symptoms of mediator release.
Dependencies are inferred from the claim text.